Document is current

Any future updates will be listed below

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia

Crossref DOI link: https://doi.org/10.1186/s12962-016-0060-5

Published Online: 2016-10-13

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark